title: Cancer therapy using oligonucleotide-based STAT3 inhibitors: will they deliver?
authors.affiliation: Department of Cancer Immunotherapeutics & Tumor Immunology, Beckman Research Institute at City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA, 91010, USA. mkortylewski@coh.org.
authors.forename: Marcin
authors.initials: M
authors.lastname: Kortylewski
authors.forename: Sergey
authors.initials: S
authors.lastname: Nechaev
mesh_terms: D000818:Animals; D015972:Gene Expression Regulation, Neoplastic; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D009369:Neoplasms / Q000235:genetics / Q000276:immunology / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D009841:Oligonucleotides / Q000378:metabolism*; D016376:Oligonucleotides, Antisense / Q000378:metabolism; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000378:metabolism*; D050796:STAT3 Transcription Factor / Q000235:genetics / Q000378:metabolism*; D016896:Treatment Outcome
chemical_list: D009841:Oligonucleotides; D016376:Oligonucleotides, Antisense; D034741:RNA, Small Interfering; D050796:STAT3 Transcription Factor